Embark Veterinary, Inc., a Boston, MA-based dog genetics company, raised $75m in Series B funding.
The round was led by Lydia Jett of SoftBank Vision Fund 2, with participation from previous investors F-Prime Capital, SV Angel, Slow Ventures, Freestyle Capital, and Third Kind Venture Capital.
The company intends to use the funds to expand on key hires and accelerate the development of its discovery engine.
Launched in 2015 by two brothers, Adam and Ryan Boyko, Embark provides dog DNA tests for over 350 breeds, more than 200 genetic health risks, and many physical traits to empower owners, breeders, and veterinarians to make personalized care plans based on a dog’s unique genetic profile. The company’s proprietary genotyping technology analyzes 200,000 genetic markers.
Embark recently hired four new senior executives to help advance its growth goals, and is aiming to hire 150 new employees to meet aggressive sales and discovery goals.